For a pediatric patient weighing 43.8 kg, how many milliliters of the Co‑amoxiclav suspension (457 mg/5 mL) are needed to deliver a total daily dose of 90 mg/kg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Dosing Calculation for Co-amoxiclav 457mg/5mL

For a 43.8 kg pediatric patient requiring 90 mg/kg/day of amoxicillin, administer 18.3 mL of co-amoxiclav 457mg/5mL suspension twice daily (9.15 mL per dose).

Calculation Breakdown

The FDA-approved dosing for the high-dose co-amoxiclav formulation (600 mg/42.9 mg per 5 mL) explicitly states 90 mg/kg/day divided every 12 hours for pediatric patients 3 months and older 1. Your preparation (457 mg/5 mL) contains less amoxicillin per volume, requiring adjustment.

Step-by-step calculation:

  • Total daily dose needed: 43.8 kg × 90 mg/kg = 3,942 mg amoxicillin per day
  • Dose per administration (twice daily): 3,942 mg ÷ 2 = 1,971 mg per dose
  • Volume per dose: (1,971 mg ÷ 457 mg) × 5 mL = 21.6 mL per dose
  • Total daily volume: 21.6 mL × 2 = 43.2 mL per day

However, note the critical formulation discrepancy: The 457 mg/5 mL preparation you're using is NOT the FDA-approved high-dose formulation. The FDA label explicitly warns that different co-amoxiclav suspensions are not interchangeable due to varying clavulanate ratios 1.

Critical Formulation Considerations

The FDA-approved 600 mg/42.9 mg per 5 mL formulation is specifically designed for 90 mg/kg/day dosing with appropriate clavulanate levels (6.4 mg/kg/day) 1. Your 457 mg/5 mL preparation likely has a different clavulanate ratio, which may affect:

  • β-lactamase inhibition adequacy
  • Gastrointestinal tolerability
  • Clinical efficacy against resistant pathogens

If treating moderate-to-severe infection, recent antibiotic exposure, daycare attendance, or age <2 years - conditions where high-dose therapy is indicated 2 - strongly consider obtaining the FDA-approved 600 mg/42.9 mg per 5 mL formulation instead.

Administration Guidelines

  • Give at the start of meals to minimize gastrointestinal intolerance and enhance clavulanate absorption 1
  • Shake suspension vigorously before each dose 1
  • Duration: 10 days for most indications 3, 2
  • Monitor for clinical improvement within 48-72 hours 3

Common Pitfall

The most frequent error is assuming all co-amoxiclav suspensions are equivalent. They are not 1. The clavulanate component varies significantly between formulations, affecting coverage of β-lactamase-producing Haemophilus influenzae and Moraxella catarrhalis - key pathogens in pediatric respiratory infections 2, 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.